Valion Bio (VBIO) Q3 2025 Earnings Report

175 Followers

Previous Report: Q2 2025

Next Report: Q4 2025

VBIO Q3 2025 EPS Results

Actual EPS-$49.14

Consensus EPS―

Beat/Miss―

One Year Ago EPS-$97.75

VBIO Q3 2025 Revenue Results

Actual Revenue$146.00K

Expected Revenue―

Beat/Miss―

YoY Revenue Growth+15.87%

Earnings Announcement Details

QuarterQ3 2025

Date11/14/2025

TimeAfter Close

Conference CallFriday, November 14, 2025

VBIO Upcoming Earnings

Valion Bio's next earnings date is estimated for November 13, 2026, based on past reporting schedules.

Q3 2025 Earnings Call Audio

VBIO Q3 2025 Earnings Call

0:00 / 0:00

Q3 2025 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2025 Earnings Call Summary

Q3 2025

Earnings Call Date:Nov 14, 2025|

% Change Since:

Earnings Call Sentiment|Neutral

Tivic Health demonstrated substantial progress in its strategic transformation and development of Entolimod, improving its financial position despite experiencing increased net loss and manufacturing delays.

Company Guidance

During the third quarter of 2025, Tivic Health Systems reported significant progress in its strategic transformation towards the biopharmaceutical market, having licensed entolimod and related assets to pivot from bioelectronics to biologic pharmaceuticals. The company is focusing on entolimod as a military countermeasure for acute radiation syndrome (ARS) and has moved forward with transferring two INDs related to ARS and advanced cancer. Financially, Tivic saw revenue net of returns at $140,000 for the quarter, an increase from $126,000 in the previous year, although nine-month revenue decreased to $302,000 from $600,000 due to reduced advertising spend. The cost of sales rose to $291,000, influenced by a $230,000 inventory reserve, while gross margins excluding this reserve improved to 42% from 35%. Operating expenses increased to $2,300,000 from $1,500,000 due to heightened R&D investments and corporate costs. The net loss widened to $2,600,000 from $1,400,000, and cash reserves grew to $3,500,000, supported by additional financing tranches totaling $3,800,000 during the quarter.

Strategic Transformation

Tivic Health expanded from bioelectronics to biologic pharmaceuticals, focusing on immune system-related treatments.

Entolimod Development Progress

Transferred two INDs for Entolimod, completed cell line verification, and advanced manufacturing readiness for military countermeasure and stockpile drug.

Financial Position

Cash and cash equivalents increased to $3.5 million from $2 million, with no debt on the balance sheet.

Gross Margin Improvement

Gross margins, excluding inventory reserve, improved to 42% from 35% compared to the previous year.

VBIO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change
Nov 13, 2026	2026 (Q3)	- / -	-1.966	―
Aug 17, 2026	2026 (Q2)	- / -52.54	-54.778	4.09% (+2.24)
May 14, 2026	2026 (Q1)	- / -53.77	-62.964	14.60% (+9.20)
Mar 25, 2026	2025 (Q4)	- / -	-2.652	―
Nov 14, 2025	2025 (Q3)	- / -49.14	-97.75	49.73% (+48.61)
Aug 14, 2025	2025 (Q2)	- / -54.78	-136	59.72% (+81.22)
May 15, 2025	2025 (Q1)	- / -62.96	-429.25	85.33% (+366.29)
Mar 21, 2025	2024 (Q4)	- / -66.30	3859	-101.72% (-3925.30)
Nov 15, 2024	2024 (Q3)	- / -97.75	-629	84.46% (+531.25)
Aug 14, 2024	2024 (Q2)	- / -136.00	-2975	95.43% (+2839.00)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed